Selecta Biosciences, a clinical stage biotechnology company, completed the merger with Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company. Financial terms were not disclosed. “RNA cell therapy has the potential to overcome the challenges of using conventional, costly DNA-engineered cell therapies to treat autoimmune diseases, including their toxicity and the need for preconditioning chemotherapy. With a shared vision of bringing meaningful therapeutic options to patients with autoimmune diseases, we are confident that our novel approach can thrive under Carsten’s leadership,” Murat Kalayoglu, Cartesian Therapeutics Co-Founder and former CEO.